Combination treatment with anti-HER2 therapeutic antibody RC48, PD-1 inhibitor, radiotherapy, and granulocyte macrophage-colony stimulating factor (GM-CSF) in patient with metastatic gastric cancer: a case report

被引:1
作者
Liu, Zhuixing [1 ]
Wang, Fang [2 ]
Zhang, Yingqi [2 ]
Lu, Jun [2 ]
Yang, Yang [2 ]
机构
[1] Xian Int Med Ctr Hosp, Dept Oncol, Xian, Peoples R China
[2] Xi'an Int Med Ctr Hosp, Dept Radiotherapy & Oncol, Xian, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2024年 / 15卷
关键词
RC48; PD-1; inhibitor; stereotactic body radiotherapy; GM-CSF; gastric cancer; HER2-positive; GASTROESOPHAGEAL JUNCTION; PLUS CHEMOTHERAPY; 2ND-LINE THERAPY; SOLID TUMORS; OPEN-LABEL; ADENOCARCINOMA; IMMUNOTHERAPY; ESOPHAGEAL; SAFETY; CAMRELIZUMAB;
D O I
10.3389/fimmu.2024.1321946
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
HER2 overexpression/amplification is a prevalent driver in various types of cancer, including gastric cancer (GC). Limited options are available for patients with HER2-positive metastatic gastric cancer, particularly those who do not respond to the standard therapy of HER2 antibody trastuzumab combined with chemotherapy. Previous research suggests that combining a PD-1 inhibitor with radiotherapy and granulocyte macrophage-colony stimulating factor (PRaG regimen) may enhance the antitumor effects in patients with chemotherapy-resistant metastatic solid tumors. In this case study, we presented a potential treatment strategy of a patient having HER2-positive and PD-L1-negative gastric adenocarcinoma. The patient showed rapid tumor progression even after surgery and multiple trastuzumab plus chemotherapy treatments. To address this, we employed a novel anti-HER2 antibody called RC48 in combination with PRaG regimen therapy (PRaG3.0). The patient demonstrated a positive response after two treatment cycles and achieved a progression-free survival time of 6.5 months. This case highlights the potential of four-combination therapies for treating refractory, multiorgan, HER2-positive, PD-L1-negative metastatic gastric cancer. Additionally, varying radiation doses in targeting dual foci is critical to enhance tumor immunotherapy.
引用
收藏
页数:10
相关论文
共 53 条
[1]   Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries [J].
Allemani, Claudia ;
Matsuda, Tomohiro ;
Di Carlo, Veronica ;
Harewood, Rhea ;
Matz, Melissa ;
Niksic, Maja ;
Bonaventure, Audrey ;
Valkov, Mikhail ;
Johnson, Christopher J. ;
Esteve, Jacques ;
Ogunbiyi, Olufemi J. ;
Azevedo e Silva, Gulnar ;
Chen, Wan-Qing ;
Eser, Sultan ;
Engholm, Gerda ;
Stiller, Charles A. ;
Monnereau, Alain ;
Woods, Ryan R. ;
Visser, Otto ;
Lim, Gek Hsiang ;
Aitken, Joanne ;
Weir, Hannah K. ;
Coleman, Michel P. .
LANCET, 2018, 391 (10125) :1023-1075
[2]   Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy [J].
Apetoh, Lionel ;
Ghiringhelli, Francois ;
Tesniere, Antoine ;
Obeid, Michel ;
Ortiz, Carla ;
Criollo, Alfredo ;
Mignot, Gregoire ;
Maiuri, M. Chiara ;
Ullrich, Evelyn ;
Saulnier, Patrick ;
Yang, Huan ;
Amigorena, Sebastian ;
Ryffel, Bernard ;
Barrat, Franck J. ;
Saftig, Paul ;
Levi, Francis ;
Lidereau, Rosette ;
Nogues, Catherine ;
Mira, Jean-Paul ;
Chompret, Agnes ;
Joulin, Virginie ;
Clavel-Chapelon, Francoise ;
Bourhis, Jean ;
Andre, Fabrice ;
Delaloge, Suzette ;
Tursz, Thomas ;
Kroemer, Guido ;
Zitvogel, Laurence .
NATURE MEDICINE, 2007, 13 (09) :1050-1059
[3]   T cell exhaustion and Interleukin 2 downregulation [J].
Balkhi, Mumtaz Y. ;
Ma, Qiangzhong ;
Ahmad, Shazia ;
Junghans, Richard P. .
CYTOKINE, 2015, 71 (02) :339-347
[4]   Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial [J].
Bang, Yung-Jue ;
Van Cutsem, Eric ;
Feyereislova, Andrea ;
Chung, Hyun C. ;
Shen, Lin ;
Sawaki, Akira ;
Lordick, Florian ;
Ohtsu, Atsushi ;
Omuro, Yasushi ;
Satoh, Taroh ;
Aprile, Giuseppe ;
Kulikov, Evgeny ;
Hill, Julie ;
Lehle, Michaela ;
Ruschoff, Josef ;
Kang, Yoon-Koo .
LANCET, 2010, 376 (9742) :687-697
[5]   Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach? [J].
Bernstein, Michael B. ;
Krishnan, Sunil ;
Hodge, James W. ;
Chang, Joe Y. .
NATURE REVIEWS CLINICAL ONCOLOGY, 2016, 13 (08) :516-524
[6]   Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4) [J].
Boku, N. ;
Ryu, M. -H. ;
Kato, K. ;
Chung, H. C. ;
Minashi, K. ;
Lee, K. -W. ;
Cho, H. ;
Kang, W. K. ;
Komatsu, Y. ;
Tsuda, M. ;
Yamaguchi, K. ;
Hara, H. ;
Fumita, S. ;
Azuma, M. ;
Chen, L. -T. ;
Kang, Y. -K. .
ANNALS OF ONCOLOGY, 2019, 30 (02) :250-258
[7]   Stereotactic Ablative Radiation Therapy Combined With Immunotherapy for Solid Tumors [J].
Brooks, Eric D. ;
Schoenhals, Jonathan E. ;
Tang, Chad ;
Micevic, Goran ;
Gomez, Daniel R. ;
Chang, Joe Y. ;
Welsh, James W. .
CANCER JOURNAL, 2016, 22 (04) :257-266
[8]   Oncology Meets Immunology: The Cancer-Immunity Cycle [J].
Chen, Daniel S. ;
Mellman, Ira .
IMMUNITY, 2013, 39 (01) :1-10
[9]   Cancer incidence and mortality in China, 2014 [J].
Chen, Wanqing ;
Sun, Kexin ;
Zheng, Rongshou ;
Zeng, Hongmei ;
Zhang, Siwei ;
Xia, Changfa ;
Yang, Zhixun ;
Li, He ;
Zou, Xiaonong ;
He, Jie .
CHINESE JOURNAL OF CANCER RESEARCH, 2018, 30 (01) :1-12
[10]   Reactive capillary hemangiomas: a novel dermatologic toxicity following anti-PD-1 treatment with SHR-1210 [J].
Chen, Xuelian ;
Ma, Lanying ;
Wang, Xi ;
Mo, Hongnan ;
Wu, Dawei ;
Lan, Bo ;
Qu, Dong ;
Zhang, Hongtu ;
Huang, Jing ;
Xu, Binghe .
CANCER BIOLOGY & MEDICINE, 2019, 16 (01) :173-+